F. Hoffmann-La Roche Ltd. - Product Pipeline Review - Q4 2010

Document Sample
F. Hoffmann-La Roche Ltd. - Product Pipeline Review - Q4 2010 Powered By Docstoc
					Brochure
More information from http://www.researchandmarkets.com/reports/1464008/




F. Hoffmann-La Roche Ltd. - Product Pipeline Review - Q4 2010

Description:    F. Hoffmann-La Roche Ltd. – Product Pipeline Review – Q4 2010

                Summary

                Global Market Direct’s pharmaceuticals report, “F. Hoffmann-La Roche Ltd. - Product Pipeline
                Review - Q4 2010” provides data on the company’s research and development focus. The report
                includes information on current developmental pipeline, complete with latest updates, and features
                on discontinued and dormant projects.

                This report is built using data and information sourced from Global Markets Direct’s proprietary
                databases, Company’s corporate website, SEC filings, investor presentations and featured press
                releases, both from company and industry-specific third party sources, put together by Global
                Markets Direct’s team.

                Scope

                - F. Hoffmann-La Roche Ltd. - Brief company overview including business description, key
                information and facts, and its locations and subsidiaries.
                - Review of current pipeline of F. Hoffmann-La Roche Ltd. human therapeutic division.
                - Overview of pipeline therapeutics across various therapy areas.
                - Coverage of current pipeline molecules in various stages of drug development, including the
                combination treatment modalities, across the globe.
                - Product profiles for late stage and clinical stage products of F. Hoffmann-La Roche Ltd. with
                complete description of the product’s developmental history, mechanism of action, therapeutic
                class, target and major milestones.
                - Recent updates of the F. Hoffmann-La Roche Ltd.’s pipeline in the last quarter.
                - Key discontinued and dormant projects.
                - Latest news and deals relating to the products.

                Reasons to buy

                - Evaluate F. Hoffmann-La Roche Ltd.’s strategic position with total access to detailed information
                on its product pipeline.
                - Assess the growth potential of F. Hoffmann-La Roche Ltd. in its therapy areas of focus.
                - Identify new drug targets and therapeutic classes in the F. Hoffmann-La Roche Ltd.’s R&D
                portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
                - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
                - Exploit collaboration and partnership opportunities with F. Hoffmann-La Roche Ltd..
                - Avoid Intellectual Property Rights related issues.
                - Explore the dormant and discontinued projects of F. Hoffmann-La Roche Ltd. and identify
                potential opportunities in those areas.



Contents:

                List of Tables
                List of Figures
                F. Hoffmann-La Roche Ltd. Snapshot
                F. Hoffmann-La Roche Ltd. Overview
                Key Information
                Key Facts
                F. Hoffmann-La Roche Ltd. – Research and Development Overview
                Key Therapeutic Areas
                F. Hoffmann-La Roche Ltd. – Pipeline Review
                Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
F. Hoffmann-La Roche Ltd. – Pipeline Products Glance
F. Hoffmann-La Roche Ltd. – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
F. Hoffmann-La Roche Ltd. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
F. Hoffmann-La Roche Ltd. – Drug Profiles
MAbThera
Product Description
Mechanism of Action
R&D Progress
5-Fluorouracil + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Avastin
Product Description
Mechanism of Action
R&D Progress
Boniva
Product Description
Mechanism of Action
R&D Progress
MAbThera
Product Description
Mechanism of Action
R&D Progress
Xeloda + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Fuzeon + Optimized Background Antiretroviral Therapy
Product Description
Mechanism of Action
R&D Progress
Trastuzumab-DM1
Product Description
Mechanism of Action
R&D Progress
GDC-0449
Product Description
Mechanism of Action
R&D Progress
F. Hoffmann-La Roche Ltd. – Pipeline Analysis
F. Hoffmann-La Roche Ltd. – Pipeline Products by Therapeutic Class
F. Hoffmann-La Roche Ltd. Pipeline Products By Target
F. Hoffmann-La Roche Ltd. – Pipeline Products by Route of Administration
F. Hoffmann-La Roche Ltd. – Pipeline Products by Molecule Type
F. Hoffmann-La Roche Ltd. – Recent Pipeline Updates
F. Hoffmann-La Roche Ltd. - Dormant Projects
F. Hoffmann-La Roche Ltd. – Company Statement
F. Hoffmann-La Roche Ltd. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 08, 2010: ImmunoGen Announces Positive Interim Clinical Results Of Trastuzumab-DM1 For
Treatment Of Metastatic Breast Cancer
Sep 02, 2010: Chugai Files NDA For Xeloda For Treatment Of Advanced Or Refractory Gastric
Cancer
Aug 25, 2010: Genentech Provides Update On FDA Application For T-DM1
Aug 09, 2010: Curis Provides Update On Genentech’s Phase II Clinical Trial Of GDC-0449 In
Advanced Ovarian Cancer Patients
Jul 14, 2010: Biogen Idec And Genentech's Rituximab Shows Promise For Treatment Of Severe
ANCA-Associated Vasculitis
Jul 06, 2010: Genentech Submits BLA To FDA For Use Of Trastuzumab-DM1 In Previously Treated
Advanced HER2-Positive Breast Cancer
May 20, 2010: Genentech Reports Encouraging Data From Phase III Study Of Rituxan
Apr 15, 2010: ImmunoGen Announces Favorable Update Provided By Roche Related To
Trastuzumab-DM1 Regulatory Plans
Apr 15, 2010: ImmunoGen Announces Favorable Update Provided By Roche Related To
Trastuzumab-DM1 Regulatory Plans
Apr 15, 2010: ImmunoGen Announces Favorable Update Provided By Roche Related To
Trastuzumab-DM1 Regulatory Plans
Financial Deals Landscape
F. Hoffmann-La Roche Ltd., Deals Volume Summary, 2004 to YTD 2010
F. Hoffmann-La Roche Ltd., Deals Summary By Region, 2004 to YTD 2010
F. Hoffmann-La Roche Ltd., Deals Summary, 2004 to YTD 2010
F. Hoffmann-La Roche Ltd. Detailed Deal Summary
Asset Purchase
Meda Acquires Global Rights Of Pharmaceutical Products From Roche
Acquisition
Roche Acquires innovatis From VENTIZZ Capital Partners
Roche Acquires Additional 44.2% Stake In Genentech
Roche Diagnostics Acquires Swisslab
Roche Acquires Mirus Bio
Roche Acquires ARIUS Research
Roche Acquires Piramed
Roche Acquires Ventana Medical Systems
Roche Acquires Nimblegen
Roche Acquires BioVeris
Roche Acquires 454 Life Sciences From CuraGen
Roche Acquires Therapeutic Human Polyclonals
Dr. Reddy’s Laboratories Acquires Industrias Quimicas Falcon de Mexico From Roche
Roche Acquires GLYCART biotechnology From Gilde Healthcare Partners
Roche Acquires Igen International
Venture Financing
Intradigm Secures $18.5 Million In Series B Financing
HistoRx Secures $6 Million In Series B Financing
Cylex Secures $20.5 Million In Series C Financing
Proacta, Inc. completes $35 million series B financing
Cylex Secures $6.4 Million In Series B Financing
Equity Offering
Silence Therapeutics Completes Private Placement Of $24 Million
Halozyme Therapeutics Completes Private Placement Of $11 Million
Debt Offering
Roche Holdings Completes Public Offering Of 4.625% Senior Unsecured Notes For $6,691.28 Million
Roche Holdings Completes Public Offering Of 5.625% Senior Unsecured Notes For $3,504.96 Million
Roche Holdings Completes Public Offering Of Floating Rate Senior Unsecured Notes For $1,911.79
Million
Roche Holdings Completes Public Offering Of 6.5% Senior Unsecured Notes For $2,230.43 Million
Roche Holdings Completes Public Offering Of 5.5% Senior Unsecured Notes For $1,784.11 Million
Roche Holdings Completes Private Placement Of Floating Rate Senior Unsecured Notes For $3,000
Million
Roche Holdings Completes Private Placement Of Floating Rate Senior Unsecured Notes For $1,250
Million
Roche Holdings Completes Private Placement Of 4.5% Senior Unsecured Notes For $2,500 Million
Roche Holdings Completes Private Placement Of 5% Senior Unsecured Notes For $2,750 Million
Roche Holdings Completes Private Placement Of 6% Senior Unsecured Notes For $4,500 Million
Roche Holdings Completes Private Placement Of 7% Senior Unsecured Notes For $2,500 Million
F. Hoffmann-La Roche Enters Into Agreement With MGH And Harvard University
b3 bio Enters Into Research Collaboration with Roche
Galapagos Enters Into Strategic Alliance With Roche Holding
AnaptysBio Enters Into Co-Development Agreement With Roche
Evolva Enters Into Drug Discovery Agreement With Roche
Psynova Neurotech Enters Into Research And Licensing Agreement With Roche
EpiVax Enters Into Collaboration Agreement With Roche
SRI International Enters Into Research Agreement With Roche
Fluofarma Enters Into Co-Development Agreement With Roche
QIAGEN Enters Into An Agreement With Roche And Idaho Technology
Enigma Diagnostics Enters Into An Agreement With Roche Molecular Systems
Adimab Enters Into An Agreement With Roche
Tekmira Pharmaceuticals Enters Into Co-Development Agreement With Roche
Synosia Therapeutics Enters Into An Agreement With Roche
Plexxikon Enters Into An Agreement With Roche
Synta Pharmaceuticals Enters Into An Agreement With Roche
Fujirebio Diagnostics Enters Into An Agreement With Roche Diagnostics
Roche Enters Into An Agreement With Axiogenesis
Exiqon Signs An Agreement With Roche Diagnostics
Roche Signs An Agreement With Glycart And Genentech
Exiqon And Roche Diagnostics Enter Into Partnership
Arcxis Biotechnologies Enters Into Agreement With Roche Molecular
Response Biomedical Signs An Agreement With Roche Diagnostics
Roche Signs Distribution Agreement With DxS
Abbott Laboratories Enters Into Agreement With Genentech, OSI And Roche
Roche Diagnostics Signs An Agreement With ARK Diagnostics
Roche Signs An Agreement With ACEA Biosciences
Roche Signs Licensing Agreement With Ortho-Clinical Diagnostics And Novartis Vaccines &
Diagnostics
NOXXON Pharma Enters Into Co-Development Agreement With Roche
Asuragen Pharmacogenomic Services Enters Into Licensing Agreement With Roche Molecular
Systems
Quidel Enters Into An Partnership With Roche Pharma
Osmetech Licenses Hot Start Polymerase Technology From Roche
Chugai Pharmaceutical Signs Agreement With Roche
Clinical Data Signs An Agreement With Roche Diagnostics
Molecular Partners Enters Into Collaboration Agreement With Roche
BD Biosciences Enters Into An Agreement With Roche
QIAGEN Enters Into Licensing Agreement With Roche Diagnostics
Roche Diagnostics Enters Into Agreement With Protedyne
Roche Diagnostics Signs An Agreement With Multilyte
Synosis Therapeutics Enters Into An Agreement With Roche
Elder Pharmaceuticals Enters Into Co-Marketing Agreement With F. Hoffmann-La Roche
Xenon Enters Into Research Agreement With Roche
Plexxikon Enters Into An Agreement With Roche
Roche Diagnostics Enters Into Agreement With OraSure Technologies
Beckman Coulter Signs Licensing Agreement With Roche Diagnostics
Roche Signs An Agreement With Ipsen
Roche Enters Into Co-development Agreement With Actelion
Evotec Enters Into Co-Development Agreement With Roche
Entelos Enters Into Research Agreement With Roche
Takeda Pharmaceutical Company Enters Into Research Agreement With ARIUS Research
Roche Signs An Agreement With Amira Pharmaceuticals
Roche Enters Into An Research Agreement With CC-SPMD
Roche Signs An Agreement With BioCryst Pharmaceuticals
Roche Amends Co-Development Agreement With Protein Design
Roche Diagnostics Signs An Agreement With Response Biomedical
Roche Diagnostics Signs An Agreement With Amplimedical
Roche Diagnostics Signs An Agreement With Exiqon
Roche Signs An Agreement With 454 Life Sciences
Roche Diagnostics Signs An Agreement With bioMerieux
Osmetech Signs A Non-Exclusive License Agreement With Roche Diagnostics
Roche and GlaxoSmithKline Announce Promotion Agreement For Xenical
Lay Line Genomics Enters Into Collaboration Agreement With Roche
Roche Enters Into Co-Development Agreement With BioTie
Epigenomics Expands Agreement With Roche Diagnostics
Roche Signs An Agreement With deCODE genetics
Oxford BioMedica Extends Collaboration With Arius Research
Roche Signs An Agreement With Pharmasset
Roche Signs An Agreement With Japan Tobacco
Roche Diagnostics Signs Licensing Agreement With Institut Pasteur And Bio-Rad Laboratories
Roche Enters Into Co-Development Agreement With Protein Design Labs
Roche Diagnostics Enters Into An Agreement With Sysmex Deutschland
Anadys Pharmaceuticals Enters An Agreement With Roche
Roche Diagnostics Signs An Agreement With Ortho-Clinical Diagnostics
Roche Diagnostics Signs An Agreement With Inverness Medical
Roche Diagnostics Signs an Agreement with Hitachi
Genentech Enters Into Research Agreement With Roche
Roche Enters Into Co-Development Agreement With ArQule
Accentia BioPharmaceuticals Enters Into Distribution Agreement With Arius Pharmaceuticals
Dade Behring Enters Into Sublicense Agreement With Roche Diagnostics
AEterna Zentaris Enters Into Agreement With Roche
Roche Terminates Its Agreement With PDL BioPharma
Roche Terminates Its Agreement With PDL BioPharma
Roche Terminates An Agreement With Trimeris
Maxygen Terminates Its Agreement With Roche
Maxygen Terminates Its Agreement With Roche
Roche Diagnostis Terminates Its Agreement With Nicholas Piramal India
Genmab Terminates Co-Development Agreement With F. Hoffmann-La Roche
Roche Terminates Co-Development Agreement With Actelion
Licensing Agreements
Dana-Farber & Sanford-Burnham Enters Into Licensing Agreement With Genentech & Roche
Afferent Pharmaceuticals Enters Into Licensing Agreements With Roche
Aegis Therapeutics Enters Into License Agreement With Roche
Roche Expands Licensing Agreement With Alnylam
SurModics Enters Into License and Development Agreement With F. Hoffmann-La Roche And
Genentech
Roche Molecular Systems Enters Into A Licensing Agreement With Biosearch Technologies
PTC Therapeutics Enters Into Licensing Agreement With F. Hoffmann-La Roche
Raptor Pharmaceuticals Enters Into An Agreement With Roche
MDRNA Enters Into Licensing Agreement With Roche
Genentech Enters Into Licensing Agreement With F. Hoffmann-La Roche
Roche Diagnostics Amends Its Agreement With Exiquon
Sangamo BioSciences And Sigma-Aldrich Signs An Agreement With Roche
BioInvent And ThromboGenics Enter Into An Agreement With Roche
Roche Diagnostics Enters Into Licensing Agreement With BIOTECON Diagnostics
Roche Enters Into Licensing Agreement With Alnylam Pharmaceuticals
Toyama Chemical Enters Into Licensing Agreement With Roche
EastPharma Enters Into Licensing Agreement With Roche
Roche Enters Into Licensing Agreement With Transgene
GlaxoSmithKline Signs A Licensing Agreement With F. Hoffmann-La Roche
BioXell Enters Into Licensing Agreement With Roche
Affymetrix Amends Its License Agreement With Roche
Lonza Group Enters Into Research And Licensing Agreement With Roche
Roche Diagnostics Signs An Agreement With ThromboGenics And Geymonat
Roche Signs Licensing Agreement With InterMune
ARIUS Research Enters Into Licensing Agreement With Genentech
Roche Enters Into Licensing Agreement With Hetero Drugs
Innogenetics Signs An Agreement With Roche Diagnostics
Applied Biosystems Expands PCR Licensing Program With Roche
Roche Diagnostics Expands Licensing Agreement With Applera
Miikana Enters Into Licensing Agreement With Roche Holding
Roche Enters Into An Agreement With Plethora Solutions
Genomic Health Enters Into Licensing Agreement With Roche Molecular Systems
Crucell And DSM Biologics Enters Into Licensing Agreement With Roche
Roche Enters Into Licensing Agreement With Cell Therapeutics
Celgene Enters Into Patent Licensing Agreement With Barr, Mylan Bertek, Ranbaxy And Roche
Emisphere Technologies Enters Into Licensing Agreement With Roche
Chiron Enters Into Licensing Agreement With Roche
Roche Enters To Technology Licensing Agreement With GLYCART biotechnology
            Cepheid Signs An Agreement With Roche
            ARIUS Research Enters Into Licensing Agreement With Ocimum Biosolutions
            Isotechnika Amends Licensing Agreement With Roche Holding
            BioVision Enters Into Licensing Agreement With Roche
            Incyte Enters Into Licensing Agreement With Roche Diagnostics
            Roche Terminates Its Licensing Agreement With Toyama Chemical
            Nippon Shinyaku Terminates Licensing Agreement With Roche Holdings
            ImmunoCellular Therapeutics Enters Into Option Agreement With Roche
            Gilead Sciences Terminates Licensing Agreement With Roche
            Roche Terminates Licensing Agreement With Isotechnika
            Appendix
            Methodology
            Coverage
            Secondary Research
            Primary Research
            Expert Panel Validation
            Contact Us
            Disclaimer



Ordering:   Order Online - http://www.researchandmarkets.com/reports/1464008/

            Order by Fax - using the form below

            Order by Post - print the order form below and sent to

                         Research and Markets,
                         Guinness Centre,
                         Taylors Lane,
                         Dublin 8,
                         Ireland.
                                                           Page 1 of 2

Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-
1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit

http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.


               Product Name:           F. Hoffmann-La Roche Ltd. - Product Pipeline Review - Q4 2010
               Web Address:            http://www.researchandmarkets.com/reports/1464008/
               Office Code:            OC8HNONKPVSUY

Product Formats
Please select the product formats and quantity you require:


                                   Quantity
               Electronic -
                                         EURO €388.00
               Single User:
               Electronic - Site
                                         EURO €775.00
               License:
               Electronic -
                                         EURO €1,163.00
               Enterprisewide:




Contact Information
Please enter all the information below in BLOCK CAPITALS


      Title:                  Mr              Mrs           Dr           Miss                 Ms       Prof

      First Name:                                                  Last Name:

      Email Address: *

      Job Title:

      Organisation:

      Address:

      City:

      Postal / Zip Code:

      Country:

      Phone Number:

      Fax Number:

     * Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
                                                              Page 2 of 2

Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

          Pay by credit card:                     American Express

                                                  Diners Club

                                                  Master Card

                                                  Visa
                                           Cardholder's Name

                                           Cardholder's Signature

                                           Expiry Date

                                           Card Number

                                           CVV Number

                                           Issue Date
                                           (for Diners Club only)




          Pay by check:                    Please post the check, accompanied by this form, to:

                                           Research and Markets,
                                           Guinness Center,
                                           Taylors Lane,
                                           Dublin 8,
                                           Ireland.


                                           Please transfer funds to:
          Pay by wire transfer:
                                           Account number                   833 130 83
                                           Sort code                        98-53-30
                                           Swift code                       ULSBIE2D
                                           IBAN number                      IE78ULSB98533083313083
                                           Bank Address                 Ulster Bank,
                                                                        27-35 Main Street,
                                                                        Blackrock,
                                                                        Co. Dublin,
                                                                        Ireland.


     If you have a Marketing Code please enter it below:


           Marketing Code:


      Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
     http://www.researchandmarkets.com/info/terms.asp



                                              Please fax this form to:
                                  (646) 607-1907 or (646) 964-6609 - From USA
                          +353 1 481 1716 or +353 1 653 1571 - From Rest of World

				
DOCUMENT INFO